To include your compound in the COVID-19 Resource Center, submit it here.

No takers for Genmab's zalutumumab

Genmab A/S (CSE:GEN) said it will wind down its

Read the full 92 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE